CoPharma Purchases Marathon Biopharmaceuticals Assets from Ligand
Under the terms of the transaction, Seragen Inc., another Ligand subsidiary, has entered into a long-term supply contract with CoPharma for the manufacture of ONTAK. In return, CoPharma will perform certain process and production development work for Seragen for the next-generation ONTAK product. CoPharma will also provide continued contract manufacturing services to Marathon's existing customers.
Marathon is a contract manufacturer of recombinant proteins and peptides. The company employs over 50 people at its 65,000 square-foot Hopkinton facility, which is FDA approved and is currently manufacturing ONTAK, a Ligand product currently sold in the U.S. for the treatment of patients with cutaneous T-cell lymphoma (CTCL).
CoPharma, Inc. is a pharmaceutical company that applies its expertise in manufacturing, preclinical and clinical affairs to actively manage the drug development process through joint ventures with discovery-based companies.
Ligand Pharmaceuticals Inc. discovers, develops, and markets new drugs that address critical unmet medical needs of patients in the areas of cancer, skin diseases, and men's and women's hormone-related diseases, as well as osteoporosis, metabolic disorders and cardiovascular and inflammatory diseases.
For more information, call David E. Robinson, President and CEO, Ligand Pharmaceuticals Inc., 10275 Science Center Dr., San Diego, CA 92121-1117. Tel: 858-550-7500. Fax: 858-550-7506.